TNF is now recognized as a typical member ofthe cytokine family with pleiotropic cellular activities (1) (2) (3) . One of the main questions regarding TNF action relates to the intracellular control mechanisms that regulate TNF response patterns in both qualitative and quantitative terms. Though expression of TNF-specific membrane receptors is given in most normal and malignant tissues (4, 5) , there is increasing evidence that control mechanisms ofTNF responsiveness are effective at both receptor and postreceptor levels . For example, control at a postreceptor level is suggested from recent data showing that TNF-induced modulation of transcriptional programs of U937 cells was dependent on the differentiation status of the cell (6) and associated with the presence of a cytosolic phosphoprotein (pp26), a presumed TNFspecific signal transducer (7) . Moreover, dominance of resistance to TNFmediated growth inhibition ofsomatic cell hybrids between TNFsensitive and -resistant cell lines was also shown to be due to postreceptor control (8, 9) . At the receptor level, there exists a quantitative relationship between receptor number and sensitivity of a given TNF responsive cell (3) . Thus, we have shown that a non-tissue-specific, protein kinase C (PKC)'-dependent control mechanism exists that downregulates TNF receptor (TNFR) function by affecting receptor affinity (10, 11) . This PKC-induced transmodulation of TNFR is associated with reduction in TNF sensitivity, which can be fully recovered by de novo synthesis and membrane expression of receptor protein (10) . To date, little is known about the mechanisms regulating TNFR expression, which is apparently constitutive in most tumor cells including leukemia and lymphoma cell lines (4, 5) . In contrast, in normal peripheral blood T lymphocytes, TNF-R expression is activation dependent (12) . IFN-y has been recognized as one of the exogenous stimulatory signals of TNFR expression (5, 13) . We have here identified protein kinase A (PKA) as one of the endogenous regulatory elements that control TNFR expression by a mechanism independent of and antagonistic to the previously described PKC-mediated control of receptor affinity (10) .
Materials and Methods
Reagents. N-2-0-dibutyryladenosine 3'5'cyclic monophosphate (DBcAMP), 8-bromoadenosine 3'5'cyclic monophosphate (8-Br-cAMP), 3-isobutyl-l-methyl-xanthine (IBMX) and 1-oleyl-2-acetyl rac-glycerol (OAG) were from Sigma Chemical Co., Munich, FRG . N-[2-(methylamino) ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-8) was from Seikagaku America, Inc., St. Petersburg, FL.
Cytokines . Purified rTNF-a, lymphotoxin (LT, TNF-/3), IFN -'Y, and IFN-a were provided by Dr. G. Adolf, Boehringer Ingelheim, Vienna, Austria . TNF, LT, IFN-y and IFN-a were iodinated by the lactoperoxidase method as described (5, 14) , with the exception that iodination ofIFN-a was performed in a sodium acetate buffer at pH 5.5. The specific radioactivity of the radioiodinated cytokines was 20-50 pCi/ug. Bioactivity of the iodinated material was determined as described and was always >60% (5) .
Cells and Culture Conditions . All cell lines used in this study were obtained from the American Type Culture Collection (Rockville, MD) . Cells were maintained in Click's/RPMI 1640 culture medium (Biochrom, Berlin, FRG) supplemented with 5% FCS, 10 mM Hepes, pH 7.3, and 50 /M 2-ME (5, 10) .
PBMC were isolated from Ficoll-separated blood leukocytes by plastic adherence for 2 h at 37'C. Purity of the preparations obtained was >95%, as controlled by direct immunofluorescence flow cytometry (EPICS C) using the Mo 2 antibody (Coulter Electronics, Krefeld, FRG). After cell culture, the adherent cells were kept for 15 min on ice and subsequently removed by vigorous pipetting .
BindingAssays. Determinations ofbinding capacities using iodinated cytokines were performed in triplicate essentially as described (5, 10), using saturating concentrations of the respective ligands (60 ng/ml'251TNF,' 251-LT, and '25I-IFN-a ; 10 ng/ml' 25 I-IFN-'Y) in PBS supplemented with 2% FCS and 0.02% sodium azide. Cells (1-2 x 106 in 300 ul final volume) were incubated with the radiolabeled cytokine for 1-2 h at 0'C and washed three times thereafter. In each case, nonspecific binding was determined in the presence of a 200-fold excess ofunlabeled ligand (three replicates). Saturation binding studies were performed similarly in duplicates at different concentrations ofradiolabeled ligand (10) with subsequent Scatchard analysis using the program "Enzfitter" (Elsevier, Biosoft, London, U.K.).
Results
Dibutyric-CAMP Reversibly Enhances TNF-R Expression in HL-60 Cells. 24-h treatment of HL-60 cells with the membrane-permeable cAMP derivative dibutyric-CAMP (DBcAMP) resulted in a drastic enhancement of 1251TNF and 1251-LT binding capacities, whereas specific binding for IFN-a and -y remained largely unaffected (Fig.  1) . Scatchard analysis of binding data demonstrate an enhancement in the number ofTNF Rs with an affinity comparable to that ofuntreated control cells (Fig. 1, inset) .
DBcAMP acts in a dose-dependent manner. Concentrations in the range of 40 p,M already significantly enhanced TNF binding capacity ; maximum stimulation was obtained with 0.5-1 mM of DBcAMP treatment for 24 h (data not shown). Kinetic analyses revealed that TNF binding starts to increase after 4-6 h of culture in the presence of 1 mM DBcAMP, with a peak in TNFR expression after 18-24 h (Fig. 2) , and a subsequent slow decline to 70% of maximal enhancement ofTNFR expression during the next 5 d of culture in the presence ofDBcAMP (data not shown) . However, when PKA stimulation was abrogated after 24 h of DBcAMP treatment, TNF binding capacity decreased to pretreatment values within 6 h (Fig. 2) .
Upregulation of TNF-Rs Is Not the Consequence of Terminal Differentiation andIsMediated by PKA . As CAMP is known to induce cellular differentiation in HL-60 cells into the monocyte/macrophage and/or granulocyte pathway (15) , various agents inducing differentiation were investigated for their potential to modulate TNF binding capacity. In addition to DBcAMP, a significant upregulation of TNFRs could also be induced with butyrate and retinal (Table I ). In contrast, DMSO, IFN-, y, granulocyte/macrophage (GM)-CSF, and TNF itself failed to induce a significant upregulation of TNF binding capacity. As shown previously (10) , PMA treatment caused a reduction in specific TNF binding due to PKC-mediated transmodulation of the receptors.
To ensure the central role of PKA in upregulation of TNF binding capacity, we evaluated additional modulators ofthe PKA signal pathway. These included 8-bromocAMP, which in contrast to DBcAMP, cannot be metabolized to other potentially active second messengers such as monobutyrate-CAMP and butyrate (16) . Further, the phosphodiesterase inhibitor 3-isobutyl-l-methyl-xanthine (IBMX) was tested, which is known to raise the intracellular level of endogenously produced cAMP by blocking its degradation (17) . Dibutyric-cGMP (DBcGMP) served as an additional control. As shown in Table II . PKA-mediated enhancement of TNF-R expression is reversible. HL-60 cells were cultured for 24 h in the presence of 1 mM DBcAMP, washed twice to remove the PKA activator, and culture was continued. Before treatment and during culture, at the time points indicated, aliquots were taken to determine specific TNF binding capacity. capacity of unstimulated HL-60 cells, indicating a direct involvement of protein kinases in both constitutive and cAMP-enhanced TNFR expression (Table II, Exp. 2). Sensitivity to kinase inhibitors and the selectivity of CAMP for PKA, therefore, points to a central role of PKA in control of TNF binding capacity. PKA Activation Results in Enhanced TNF-R Synthesis. Upregulation ofTNF binding capacity could be either due to a change in TNFR synthesis or, alternatively, might reflect changes in the kinetics of receptor degradation or export into the cellular membrane. To exploit these possibilities, we compared the basic receptor turnover in both untreated and DBcAMP-treated HL-60 cells. The rate of TNFR degradation was examined by blocking de novo protein synthesis with cycloheximide (CHX) . In both untreated control cells and DBcAMP pretreated cells, the decrease in TNF binding capacity followed kinetics of first order with an identical half-life of ti2 h, as indicated by the parallel and linear slopes in a semilogarithmic plot (Fig. 3) .
These data already suggested that upregulation of TNFRs by PKA might reflect a proportional enhancement in receptor synthesis rather than changes in turnover rate . As specific TNFR probes for direct determination of expression at transcriptional or posttranscriptional levels are not yet available, protein synthesis-dependent recovery of specific TNF-binding capacity upon proteolytic digestion ofTNF Rs was studied to estimate the rate of TNFR synthesis. We investigated the reexpression of TNFRs in HL-60 cells by determining the specific membrane TNF binding capacity upon trypsin treatment, which caused a 70-95% reduction in functional TNFRs. However, in contrast to U937 cells (10), HL-60 cells contain a significant intracellular pool of TNFRs. Thus, initial experiments revealed that upon tryptic digestion of TNFRs, 10-40% of pretreatment TNFR levels can be transiently regained in CHXpretreated (10 p.g/ml) HL-60 cells within 1 h after trypsin treatment (data not shown). Therefore, in further experiments the difference in TNFR membrane reexpression in the absence and presence of CHX was taken for evaluation of receptor de novo synthesis. Fig. 4 shows that the de novo protein synthesis-dependent TNFR membrane expression of DBcAMP-treated cells increased eightfold as compared with that of the untreated control HL-60 cells. (18), it was of interest to investigate whether TNFR transmodulation by PKC is still effective under conditions of TNFR upregulation by PKA. Accordingly, HL-60 cells were either left untreated or were pretreated for 24 h with DBcAMP, and subsequently, TNF binding capacity was determined in both groups before as well as 0.5 and 24 h after transient stimulation of PKC by pulse treatment with OAG. The data obtained revealed that upon OAG treatment, TNFbinding capacity was reduced to a similar extent in both cAMP-treated (6% of control) and untreated (10% of control) HL-60 cells (Table  III) not interfere with either normal or with PKA-enhanced TNFreceptor synthesis, but rather controls the binding affinity of membrane-expressed receptor molecules. Cell Specificity of PKA-induced Receptor Upregulation. A number of different tumor cell lines were investigated for DBcAMP stimulation of TNFR synthesis. 5 of 15 investigated cell lines of distinct tissue origin did respond with a significant enhancement in specific TNF binding capacity ; aside from two human myeloid TNF producer cell lines, U937 and HL-60, the human erythroblastoid leukemia cell K562 as well as the murine T cell lymphoma EL4 and a human colon carcinoma cell line (SW480) were found to be responsive (Table IV) , suggesting that this mechanism of receptor control is neither species nor strictly tissue specific. However, the data shown in Fig. 4 suggest that PKA-mediated upregulation of TNFR expression is particularly effective in tumor cells derived from myeloid origin . Therefore, we investigated whether in normal peripheral blood monocytes/macrophages TNFR expression is also controlled by PKA. On average, purified, unstimulated monocytes constitutively expressed "1,000 TNFR (data not shown) . Similar to established cell lines, PKA stimulation was effective in normal peripheral blood monocytes, yielding, on average, a threefold (281 t 54%) enhancement of TNFR (Table IV) . Again, affinity of TNFR remained unchanged upon DBcAMP treatment of the cells, as indicated by the parallel slopes of the Scatchard diagram shown in Fig. 5 .
Discussion
The present investigations aimed at an identification of intracellular control mechanisms of TNFR expression, a condition requisite for TNF responsiveness. The data show that activators of PKA can selectively upregulate TNFR expression, pre- Respective binding data .
bound (pM) t cells of the myeloid lineage, whereas protein kinase inhibitors interfere with TNFR expression . In HL-60 cells, on average, a sevenfold stimulation was achieved after 24 h of treatment with optimal concentra tions of DBcAMP (Table II) , yielding -28,000 receptors/cell . As expected, the binding capacity for 1251-LT was enhanced in parallel, which is in agreement with the current view of a single cellular membrane receptor binding both cytokines (19) . In contrast, expression of both types of IFN receptors (u, y) proved to be insensitive to this stimulation regimen (Fig. 1) .
Kinetics of receptor degradation after blocking of protein synthesis with CHX was found to be of first order, suggesting that TNFR degradation might simply reflect normal cellular membrane turnover (20) . Half-life of TNFRs of -2 h was identical in both CAMP-treated and untreated HL-60 cells (Fig . 3) , indicating that degradation of TNFRs increases in parallel with an increase in TNFR number triggered by PKA stimulation. This leads to the conclusion that PKA activation most likely causes an enhancement of TNFR synthesis. At present, due to lack of appropriate probes, TNFR gene transcription and/or translation cannot be directly analyzed . Therefore, estimates on the rate of TNFR synthesis have to rely on the indirect approach of quantification of protein synthesis-dependent acquisition of TNF binding capacity. The different membrane reexpression rates upon removal ofTNFR by tryptic digestion (Fig. 4 ) strongly argue for enhanced synthesis ofreceptor proteins in cAMP-treated as compared with untreated HL-60 cells. Moreover, complete recovery from PKC-mediated transmodulation of TNFR in cAMP-treated cells (Table III) further supports this reasoning. The latter experiments also suggest that PKC-mediated transmodulation and PKA-mediated receptor upregulatiôn are independent ofeach other and can be effective at the same time, resulting in a phenotypically antagonistic action .
Aside from DBcAMP, sodium butyrate and retinal were also found to upregulate TNFRs in HL-60 cells. While retinal is known to activate PKA (21), butyrate is thought to mainly affect histone deacetylation (22) . As DBcAMP is known to become processed intracellularly, resulting in the release of monobutyric cAMP and butyrate (16) , it is conceivable that DBcAMP is effective exclusively via intracellular release of butyrate and not via activation of PKA. The latter possibility could be excluded, as 8-Br-CAMP, an additional activator of PKA, and IBMX, an inhibitor of degradation of endogenously produced CAMP (17) , also enhanced TNF binding capacity, whereas DBcGMP was ineffective. Moreover, H-8, a potent inhibitor of PKA, completely abolished CAMP upregulation ofTNFR (Table 11) . Whether CAMP and butyrate enhance TNFR expression via shared signal pathways or act completely independent of each other, is unknown at present.
Since DBcAMP, retinal, and butyric acid are known to induce differentiation in HL-60 cells (15) , upregulation of TNFR expression in these cells might represent a consequence of an altered differentiation status triggered by these various agents . However, in regard to TNFR expression, both DBcAMP (Fig. 2) and butyrate action (data not shown) were fully reversible. Furthermore, maximum effects ofDBcAMP and butyrate were observed after 24 h of treatment, at which time only N5% of the HL-60 cells are considered to be differentiated (23) . Apparently, enhancement of TNFRs is not linked to irreversible processes of cellular differentiation . These suggestions are supported by the finding that TNFRs are upreguaated by activation of PKA in tumor cell lines of myeloid origin and in normal peripheral blood monocytes/macrophages representing various stages of the myelomonocytic differentiation pathway (Table IV, Fig. 5 ). Various activators of PKA as well as IBMX were also effective in these cells (data not shown) .
Recent work from our laboratory (24, 25) and from others (26) provided evidence that production of TNF itself is also controlled by protein kinases. Thus, activation of PKC leads to induction of TNF mRNA and/or secretion of the protein (24, 25) . PKA, on the other hand, has been demonstrated to act as a negative regulator on TNF production (26) . These effects are exactly opposed to those of the respective protein kinase on TNFR synthesis (PKA) and its functional status (PKC). As shown here, both mechanisms can be effective in a single cell type, that is per se TNF sensitive and a potential TNF producer, such as normal peripheral blood monocytes as well as the monocytec cell lines HL-60 and U937 (5, 6, 27, 28) . Moreover, as both protein kinases apparently participate in TNF signal transduction (7, 24, 29) , we suggest that a regulatory circuit could be effective in the following way: activation of PK-A results in an enhancement of TNFR expression paralleled with inhibition of TNFproduction; on the other hand, activation of PKC induces production and secretion of mature (17 kD) TNF and simultaneously inactivates expressed TNF membrane receptors (transmodulation), thereby inducing TNF resistance (10) . As TNFRs are ubiquitously expressed (4, 5) and many different cell types are potential TNF producers (24, (30) (31) (32) , such an antagonistically acting regulatory circuit may be used to control autocrine stimulation, and may enable cells to completely switch from a signal transmitter (TNF producer) to a receiver (TNF responder) status .
Summary
We have investigated control mechanisms of TNF receptor expression (TNFR) in various human tumor cells and normal peripheral blood monocytes. Activators of protein kinase A (PKA) signal transduction pathways were found to enhance TNFR expression up to sevenfold, whereas in the same cells, IFN-C1 and -y receptors remained unaffected. Inhibitors of protein kinases downregulate both constitutive and CAMP-enhanced TNFR expression. Binding studies revealed an increase in TNF R numbers without a change in receptor affinity. Both, direct activators of PKA and inhibitors ofphosphodiesterase, raising intracellular levels ofCAMP, were found to be effective . As activation of PKA does not slow down the degradation rate of TNFRs, but rather enhances protein synthesis-dependent reexpression ofTNFRs after transient PKC-mediated transmodulation and after tryptic digestion of TNF Rs, it is concluded that PKA stimulates TNFR synthesis . Maximum TNFRs enhancement is reached after 24 h of stimulation and is reversible, suggesting that receptor upregulation is not linked to irreversible steps ofcellular differentiation. PKA-mediated enhancement ofTNFR expression was predominantly observed in normal peripheral blood monocytes and tumor cell lines of myeloid origin. As in these typical TNF producer cells, the production ofTNF is also controlled by PKA and PKC, a regulatory circuit is proposed, by which these two independent signal pathways antagonistically regulate TNF production and, at the receptor level, TNF sensitivity.
